Clinical Trials Logo

Clinical Trial Summary

This is a prospective, non-interventional, longitudinal study of the natural history and function of approximately 60 patients with MTM from the United States, Canada and Europe. The duration of the study, including the enrollment period, will be 36 months. Data from the study will be used to characterize the disease course of MTM and determine which outcome measures will be the best to assess the efficacy of potential therapies.


Clinical Trial Description

This is a prospective, non-interventional, longitudinal study of the natural history and function of patients with MTM. The study duration is 36 months. The enrollment period will be 12 months and each patient will be assessed over 24 months. Data will be analyzed at baseline and annually thereafter and reports will be prepared based on these analyses. A final report will summarize findings after all patients have completed 24 months of follow-up. Assessments performed in this study will be based on the age and ambulatory status of the patient. The assessments will also be adjusted to account for the variability in both phenotypes and age of the patients who may participate in this study. Patients will be evaluated at Baseline, Month 6, Month 12 and Month 24. It is anticipated that approximately 60 patients from the United States, Canada and Europe will be included in this study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02057705
Study type Observational
Source Valerion Therapeutics, LLC
Contact
Status Completed
Phase
Start date February 2014
Completion date June 26, 2017

See also
  Status Clinical Trial Phase
Recruiting NCT04064307 - Myotubular and Centronuclear Myopathy Patient Registry
Completed NCT01817946 - Myotubular Myopathy Genetic Testing Study N/A
Recruiting NCT00272883 - Molecular and Genetic Studies of Congenital Myopathies